However, specific molecular target therapy is currently used in AdCC, and the drug used in clinical practice is Lenvatinib, which is a broad-spectrum tyrosine kinase inhibitor (TKI) capable of mainly blocking VEGFR [12]. Here, KDR is linked to adrenocortical carcinoma, hereditary.